Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHR | P34981 | 4/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL7609568 | 0.95 | TRHR (0.33) | TRHRITGB1ITGA4 | |
| Histidine SCHEMBL10455821 | 0.89 | SLC7A5 (0.34) | — | |
| Histidine SCHEMBL9719668 | 0.89 | SLC7A5 (0.34) | — | |
| D-Histidine SCHEMBL11606906 | 0.86 | SLC7A5 (0.35) | — | |
| Histidine SCHEMBL2586203 | 0.86 | SLC7A5 (0.35) | — | |
| Histidine SCHEMBL2586200 | 0.86 | SLC7A5 (0.35) | — | |
| Histidine SCHEMBL27902238 | 0.86 | SLC7A5 (0.35) | — | |
| Histidine SCHEMBL16444321 | 0.84 | CYP3A4 (0.32) | — | |
| Histidine SCHEMBL5583260 | 0.82 | CYP3A4 (0.31) | — | |
| Histidine SCHEMBL10828038 | 0.82 | CYP1A2 (0.33) | ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6815425-B1 | ADMINISTERED WITH N-TERT-BUTYL- ALPHA -(2-SULFOPHENYL)NITRONE (SPBN); NEUROPROTECTANTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2004-11-09 | — | — | US | disclosed |
| US-20040214781-A1 | Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same | MEYERHOFF JAMES L (US) | 2004-10-28 | — | — | US | disclosed |
| US-6441133-B1 | PURE RECEPTOR PROTEIN OF GIVEN AMINO ACID SEQUENCE | ASTRAZENECA CANADA INC. (CA) | 2002-08-27 | — | — | US | disclosed |
| WO-2001028578-A2 | A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME | WRAIR (US) | 2001-04-26 | — | — | WO | disclosed |
| EP-0951479-A1 | TRH RECEPTOR | Astra Pharma Inc. (CA) | 1999-10-27 | — | — | EP | disclosed |
| WO-1998024818-A1 | NOVEL TRH RECEPTOR | ASTRA PHARMA INC. (CA) | 1998-06-11 | — | — | WO | disclosed |